◈ Nootpedia
Compact view
Research pass: medium Peptide · Injectable SKIP-PERMANENT HIGH

Teriparatide

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-PERMANENT HIGH

Dylan is 20 with peak BMD intact and no osteoporosis indication; teriparatide is a fracture-prevention drug for severe low BMD populations and offers nothing for a young athlete. Would change only if a serious fracture-prone osteoporotic state emerged decades from now.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    NOT-RELEVANT

    Peak BMD intact, no fracture risk, no osteoporosis indication. Teriparatide does nothing for cognition, MMA performance, or longevity in a healthy young adult — it's a targeted fracture-prevention drug. Open-epiphysis caution and the residual osteosarcoma question (even with reassuring human data) make off-label use in a 20yo with no indication unjustifiable. Skip permanently for this profile.

  • 30-50, executive maintenance
    NOT-RELEVANT

    unless rare premature osteoporosis (e.g., chronic glucocorticoid therapy, premature menopause, hypogonadism with documented BMD loss).

  • 50+, mild cognitive decline
    NOT-RELEVANT

    for cognition. Becomes RELEVANT only if T-score < -2.5 with fracture risk — at that point standard endocrinology indication.

  • Anxiety-prone
    N

    applicable.

  • High athletic load, tested status
    NOT-RELEVANT

    in healthy athletes. Off-label use for slow-healing stress fractures or non-unions in older athletes is reported but is a clinical decision with an orthopedist, not a biohacking optimization.

  • Sleep-disordered
    N

    applicable.

  • Recovery-focused (post-injury, post-illness)
    WATCH-LIST

    for older athletes (45+) with delayed-union fractures or atypical femur fractures — small evidence base supports off-label use under orthopedic supervision. Not relevant for younger athletes whose fracture healing is normal.

  • Strength/anabolic-focused
    NOT-RELEVANT

    Teriparatide builds bone, not muscle — it has no anabolic effect on lean mass or performance.

  • Postmenopausal severe osteoporosis (T < -2.5 + prior vertebral fracture)
    STRONG-CANDIDATE

    / standard of care. A-tier evidence for fracture reduction; sequence into antiresorptive after 18-24 months.

  • Older male hypogonadal-osteoporosis
    STRONG-CANDIDATE

    FDA-approved indication; meaningful BMD gain; fracture reduction extrapolates from the women's RCT data.

  • Glucocorticoid-induced osteoporosis (chronic prednisone)
    STRONG-CANDIDATE

    Saag 2007 establishes superiority over alendronate.

▸ Subjective experience (deep)

Largely uneventful for most users. The notable subjective events:

  • First-dose orthostatic hypotension — the most distinctive feature. ~5% of users get transient lightheadedness, palpitations, or near-syncope within 4 hours of the first few injections. Recommendation is to take the first dose seated/recumbent, near a place where you can lie down. Usually resolves by dose 3-5.
  • Mild nausea in ~10%, often dose-related, usually transient
  • Leg cramps in ~3% — calcium/electrolyte shift related
  • Injection site reactions — minor erythema or bruising at thigh/abdomen sites; pen device is well-tolerated
  • No mood, energy, sleep, or cognitive effects reported in trials. No subjective "feeling" of bone-building.
▸ Tolerance + cycling deep dive
  • Anabolic window: Bone formation outpaces resorption for ~12-18 months, then a new equilibrium establishes and additional gain is minimal — so duration > 24 months gives diminishing returns
  • 2020 FDA update: Removed the absolute 2-year lifetime cap; clinicians may continue beyond 24 months when fracture risk continues to justify it. In practice most patients still stop at 18-24 months and sequence to antiresorptive
  • Reset/sequence: After teriparatide course → start alendronate, denosumab, or zoledronic acid immediately to lock in BMD gain. Without this step, ~50% of BMD gain reverses within 12 months
  • Re-treatment: Repeat courses are now permitted under updated label; minimal data on re-treatment efficacy
▸ Stacking deep dive

Synergistic with

  • denosumab (concurrent) — DATA trial showed additive BMD effect; emerging combination strategy in highest-risk patients
  • bisphosphonate / denosumab (sequential, post-teriparatide) — locks in gains, considered standard of care for severe osteoporosis
  • vitamin D + calcium — required co-administration (insufficient calcium/D blunts response and increases fracture risk despite BMD gain). Target 25(OH)D ≥30 ng/mL, calcium 1000-1200 mg/day total (diet + supp)

Avoid stacking with

  • digoxin — hypercalcemia from teriparatide can sensitize myocardium → arrhythmia
  • thiazide diuretics — additive hypercalcemia risk (HCTZ reduces urinary calcium excretion)
  • bisphosphonates concurrently (alendronate + teriparatide simultaneously) — the older Black 2003 NEJM data suggested alendronate blunted teriparatide response when given together; this was the basis for the "anabolic first, antiresorptive second" sequencing rule. Newer denosumab data complicates this picture (denosumab does NOT blunt) but the bisphosphonate caution stands

Neutral / safe co-administration

Most non-bone medications. No CYP-mediated drug interactions because teriparatide is a peptide (degraded by peptidases, not hepatic metabolism). HRT, SERMs, and most cardiac/metabolic medications can be given without interaction except as noted above.

▸ Drug interactions deep dive
  • No CYP enzyme involvement — teriparatide is a 34-amino-acid peptide cleared by non-specific proteolysis, hepatic uptake, and renal excretion of fragments. Half-life ~1 hour SC.
  • Digoxin: clinical interaction via hypercalcemia (above)
  • Calcium-raising drugs (thiazides, lithium, vitamin D analogs): additive hypercalcemia risk — monitor serum calcium
▸ Pharmacogenomics
  • No clinically relevant pharmacogenomic markers for teriparatide response. PTH1R polymorphisms have been investigated for BMD response variability with weak/inconsistent signal — not clinically actionable.
  • 23andMe data Dylan will receive in June 2026 will not contain meaningful teriparatide-response variants.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (brand) Eli Lilly Forteo via specialty pharmacy ~$3,000-3,500 / month High Insurance prior-auth required; almost always denied without DXA T-score < -2.5 + fracture history
US Rx (biosimilar) Pfenex/Alvogen Bonsity ~$1,500-1,800 / month High FDA-approved 2019 biosimilar, bioequivalent, identical mechanism
Compounding pharmacy Various 503B compounders varies Med Some sources of compounded PTH 1-34 exist but quality variable; not insurance-covered
Gray-market peptide vendors Research peptide sites $200-600/vial unverified Low Sold as "research only" recombinant PTH 1-34; potency, purity, sterility unverified; cold-chain integrity questionable; not appropriate for a year-long therapeutic course
International pharmacy Indian/Mexican pharmacies varies Low-Med Available but sterility / cold-chain concerns for a peptide injection given daily for years

For Dylan: N/A — no indication. If indicated (decades from now, hypothetical severe BMD loss), the legitimate Rx path with insurance is the only sensible route given the daily-injection-for-2-years duration.

▸ Biomarkers to track (deep)
  • Baseline (before starting):
    • DXA scan (lumbar spine + total hip + femoral neck T-scores)
    • Serum calcium (must be normal before initiation)
    • 25(OH) vitamin D (target ≥ 30 ng/mL)
    • Intact PTH (rule out primary hyperparathyroidism)
    • Alkaline phosphatase (must not be unexplained-elevated — Paget's exclusion)
    • Creatinine / eGFR
    • 24-hour urine calcium (if hypercalciuria suspected)
  • During use:
    • Serum calcium at month 1, then PRN; check 4-6 hr post-dose if symptomatic
    • 25(OH)D every 6 months
    • Bone turnover markers (P1NP, CTX) at 3 months — P1NP rise confirms anabolic response (P1NP rise > 10 mcg/L at 3 mo predicts BMD response)
    • DXA at 12 and 24 months
  • Post-cycle / sequencing decision point (24 months):
    • DXA to document gain
    • Plan transition to alendronate / denosumab / zoledronic acid within 1-3 months of stopping
▸ Controversies / open debates Live debate
  • Osteosarcoma signal — resolved or just reassured? Rat carcinogenicity data was striking (high incidence at exposures multifold above human equivalent dose). 20 years of human post-marketing data show no signal, and FDA loosened restrictions in 2020. Most endocrinologists treat the rat finding as species-specific; a minority remain cautious about decades-long latency that hasn't fully played out yet.
  • Duration cap — was 2 years arbitrary? The 2-year cap was an FDA precaution based on the rat data and the ~24-month anabolic window. Removal of the absolute cap in 2020 was data-driven but practical adoption of >24 months is still uncommon — most clinicians sequence to antiresorptive at 18-24 months as before.
  • Concurrent vs sequential combination with denosumab: The DATA and DATA-Switch trials suggest concurrent teriparatide + denosumab produces greater BMD gain than either alone, opening a "dual anabolic + antiresorptive" approach for highest-risk patients. Not yet standard of care but cost-effectiveness improving.
  • Teriparatide vs abaloparatide (Tymlos): Abaloparatide is a PTHrP analog rather than PTH itself; ACTIVE trial showed slightly faster non-vertebral fracture reduction and possibly less hypercalcemia. Class similarity is high; choice often driven by formulary and cost. See abaloparatide for specific differences.
  • Off-label fracture-healing use: Multiple case series and small RCTs suggest teriparatide accelerates healing of delayed unions, atypical femoral fractures, and pelvic insufficiency fractures. Not FDA-approved for this. Insurance won't cover. Often used in older patients with non-union under orthopedic specialist supervision.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-PERMANENT for Dylan (NOT-RELEVANT). 20yo MMA athlete with peak BMD intact has no indication; risks (open-epiphyseal-fusion caution lingers, oncologic uncertainty) outweigh nonexistent benefit. Documented for completeness as the canonical bone-anabolic peptide and reference for older-athlete fracture context.
▸ Open questions / gaps Open
  • Long-term (>10-year) human osteosarcoma latency data still accumulating — unlikely to change practice but worth tracking
  • Optimal sequencing post-anabolic course (denosumab vs alendronate vs zoledronic acid) — head-to-head data still incomplete
  • Whether sub-therapeutic "biohacker" dosing (e.g., 5-10 mcg) could produce subclinical anabolic benefit without hypercalcemia — no human data; would change my verdict for Dylan only marginally because there's still no benefit-side signal in a peak-BMD 20yo
▸ Sources (full, with our context)
Back to compact view